Pharmacogenetics of acute lymphoblastic leukemia - Frikha, Rim
29,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
15 °P sammeln
  • Broschiertes Buch

Our research focused on investigating the involvement of polymorphisms (C677T and A1298C) of the MTHFR gene in the pharmacogenetics of acute lymphoblastic leukemia (ALL), particularly with high-dose methotrexate (MTX-HD). Despite its proven clinical efficacy, the latter can cause severe toxicity. 41 young children followed for ALL were collected. Genotyping of the two variants was correlated with therapeutic response and pharmacological assays (MTX and homocysteine)While MTHFR C677T is a good marker of MTX-HD toxicity, A1298C is not. Nevertheless, no correlation between the C677T variant and…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Our research focused on investigating the involvement of polymorphisms (C677T and A1298C) of the MTHFR gene in the pharmacogenetics of acute lymphoblastic leukemia (ALL), particularly with high-dose methotrexate (MTX-HD). Despite its proven clinical efficacy, the latter can cause severe toxicity. 41 young children followed for ALL were collected. Genotyping of the two variants was correlated with therapeutic response and pharmacological assays (MTX and homocysteine)While MTHFR C677T is a good marker of MTX-HD toxicity, A1298C is not. Nevertheless, no correlation between the C677T variant and pharmacokinetic parameters during MTX-HD administrationIn conclusion, despite the debate concerning the existence of a pharmacogenetic marker for the use of MTX in clinical practice, the C677T polymorphism of the MTHFR shows promising results.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Rim Frikha; MD-PhD, Profesor Asociado de Medicina, Histología-EmbriologíaEspecialista en genética molecular en onco-hematologíaUniversidad de Sfax-Facultad de Medicina; Sfax-TúnezCHU Hedi Chaker- Servicio de Genética Médica ; Sfax-Túnez